Individualised mRNA vaccine for melanoma trialled in UK patients

26 April 2024

Dr Heather Shaw with patient Steve Young. Credit: Yui Mok/PA Wire

By Jane Kirby, PA Media

The world’s first personalised individualised neoantigen therapy (INT) for melanoma – which also has the potential to stop lung, bladder and kidney cancer – is being tested in British patients in a phase 3 trial.







Log in or join to read more

You might also like